We compared the
in vitro and
in vivo antifungal activities of D0870, a new triazole antifungal agent, with those of other antifungal agents against 8 clinical isolates of fluconazole-resistant
Candida albicans. Microdilution testing was performed according to National Committee for Clinical Laboratory Standards (NCCLS) document M27-T. Minimal inhibitory concentration of D0870 (≤0.004-1.0μg/m
l) was lower than those of fluconazole (2->64μg/m
l) and itraconazole (0.031-8.0μg/m
l). In systemic infection models with
C. albicans in normal and immunosuppressed mice, D0870 at 0.3-30mg/kg/day for 5 days after infection prolonged survival of the animals and showed the highest efficacy among the triazole antifungal agents. At pH 7 and 37°C in Sabouraud dextrose broth (SDB), D0870 inhibited the growth of
C. albicans and acted cytocidally against one of the middle-resistant strains. In an
in vivo study against this strain, D0870 at 10mg/kg/day for 5 days after infection significantly reduced kidney colony counts (2850±406→997±537 CFU/kidney, P<0.05) on day 7 after infection in comparison with those of the control mice at 24h after infection. Plasma concentration of D0870 after a single oral administration at 10mg/kg maintained a sufficient level for interpretation of
in vivo antifungal activities.
These results suggest that D0870 has strong antifungal activities against clinical isolates of fluconazole-resistant
C. albicans in vitro and
in vivo, and that these strong activities are at least partially concerned with the fungicidal action.
View full abstract